Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Arata Azuma

Showing results (21-30 of 221) with videos related to

Pageof 23
Sort By:
Clinical Medicine Insights. Circulatory, Respiratory and Pulmonary Medicine|December 17, 2016
Idiopathic Pulmonary Fibrosis: Treatment and PrognosisHajime Fujimoto, Tetsu Kobayashi, Arata Azuma
Core Evidence|September 9, 2015
Nintedanib: evidence for its therapeutic potential in idiopathic pulmonary fibrosisMinoru Inomata, Yasuhiko Nishioka, Arata Azuma
American Journal of Respiratory and Critical Care Medicine|May 3, 2013
A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis: a hidden subgroup?Hiroshi Kubo, Masaru Yanai, Arata Azuma
American Journal of Respiratory and Critical Care Medicine|June 5, 2008
Basis of acute exacerbation of idiopathic pulmonary fibrosis in Japanese patientsArata Azuma, Koichi Hagiwara, Shoji Kudoh
Oxidative Medicine and Cellular Longevity|June 6, 2013
Nrf2 is a protective factor against oxidative stresses induced by diesel exhaust particle in allergic asthmaYing-Ji Li, Tomoyuki Kawada, Arata Azuma
Pharmacology|March 25, 2011
Antipyretic and analgesic effects of zaltoprofen for the treatment of acute upper respiratory tract infection: verification of a noninferiority hypothesis using loxoprofen sodiumArata Azuma, Shoji Kudoh, Mitsuyoshi Nakashima, et al.
Pharmacology|December 24, 2009
A double-blind study of zaltoprofen for the treatment of upper respiratory tract infectionArata Azuma, Shoji Kudoh, Mitsuyoshi Nakashima, et al.
American Journal of Respiratory and Critical Care Medicine|April 2, 2020
Reply to Horita and Takeshi: Thrombomodulin Did Not Benefit Acute Exacerbation of Idiopathic Pulmonary Fibrosis in a TrialYasuhiro Kondoh, Arata Azuma, Jun Tagawa, et al.
Respirology (Carlton, Vic.)|November 6, 2012
Reply 2Tatsuji Enomoto, Midori Sugisaki, Koichiro Kamio, et al.
Contemporary Clinical Trials Communications|September 2, 2021
Design of phase 2 study of TAS-115, a novel oral multi-kinase inhibitor, in patients with idiopathic pulmonary fibrosisYasuhiko Nishioka, Sakae Homma, Takahito Okubo, et al.
Pageof 23

Showing results (21-30 of 221) with videos related to

Sort By:
Pageof 23
Clinical Medicine Insights. Circulatory, Respiratory and Pulmonary Medicine|December 17, 2016
Idiopathic Pulmonary Fibrosis: Treatment and PrognosisHajime Fujimoto, Tetsu Kobayashi, Arata Azuma
Core Evidence|September 9, 2015
Nintedanib: evidence for its therapeutic potential in idiopathic pulmonary fibrosisMinoru Inomata, Yasuhiko Nishioka, Arata Azuma
American Journal of Respiratory and Critical Care Medicine|May 3, 2013
A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis: a hidden subgroup?Hiroshi Kubo, Masaru Yanai, Arata Azuma
American Journal of Respiratory and Critical Care Medicine|June 5, 2008
Basis of acute exacerbation of idiopathic pulmonary fibrosis in Japanese patientsArata Azuma, Koichi Hagiwara, Shoji Kudoh
Oxidative Medicine and Cellular Longevity|June 6, 2013
Nrf2 is a protective factor against oxidative stresses induced by diesel exhaust particle in allergic asthmaYing-Ji Li, Tomoyuki Kawada, Arata Azuma
Pharmacology|March 25, 2011
Antipyretic and analgesic effects of zaltoprofen for the treatment of acute upper respiratory tract infection: verification of a noninferiority hypothesis using loxoprofen sodiumArata Azuma, Shoji Kudoh, Mitsuyoshi Nakashima, et al.
Pharmacology|December 24, 2009
A double-blind study of zaltoprofen for the treatment of upper respiratory tract infectionArata Azuma, Shoji Kudoh, Mitsuyoshi Nakashima, et al.
American Journal of Respiratory and Critical Care Medicine|April 2, 2020
Reply to Horita and Takeshi: Thrombomodulin Did Not Benefit Acute Exacerbation of Idiopathic Pulmonary Fibrosis in a TrialYasuhiro Kondoh, Arata Azuma, Jun Tagawa, et al.
Respirology (Carlton, Vic.)|November 6, 2012
Reply 2Tatsuji Enomoto, Midori Sugisaki, Koichiro Kamio, et al.
Contemporary Clinical Trials Communications|September 2, 2021
Design of phase 2 study of TAS-115, a novel oral multi-kinase inhibitor, in patients with idiopathic pulmonary fibrosisYasuhiko Nishioka, Sakae Homma, Takahito Okubo, et al.
Pageof 23